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Diﬀerences between clinical (cT) and pathological tumor (pT) stage occur often after radical cystectomy (RC) for muscle-invasive
bladder cancer. In order to evaluate the impact of downstaging on recurrence and survival, we selected patients from a large,
contemporary, population-based series of 1,409 patients with MIBC. We included all patients who underwent RC (N = 643)
and excluded patients who received (neo)adjuvant therapy, those with known metastasis at time of diagnosis, and those with
nonurothelial cell tumors. Disease outcomes were defined as recurrence-free survival (RFS) and relative survival (RS), as a good
approximation of bladder cancer-specific survival. After applying the exclusion criteria, 375 patients were eligible for analysis.
Tumor downstaging was found to be common after RC; in 99 patients (26.4%), tumor downstaging to non-muscle-invasive stages
at RC occurred. Hydronephrosis at baseline and positive lymph nodes at RC occurred significantly less often in these patients.
In 62 patients, no tumor was left in the cystectomy specimen. pT stage was pT1 in 20 patients and pTis in 17 patients. Patients
with tumor downstaging have about a 30% higher RFS and RS compared to those without. Consequently, tumor downstaging is a
favorable marker for prognosis after RC.
1. Introduction
The gold standard of treatment for muscle-invasive bladder
cancer (MIBC) is radical cystectomy (RC) with pelvic lymph
node dissection (PLND). A discrepancy between the initial
clinical T-stage (cT-stage) at transurethral resection of the
tumor (TURBT) and the final pathological T-stage (pT-
stage) after RC is reported in up to 76% of patients [1]. This
discrepancy may be due to factors such as poor sensitivity
of current imaging, incomplete TURBT with undersampling
of muscle tissue, and a long interval between TURBT and
RC [2, 3]. Clinical understaging of the tumor is reported in
40–49% of those undergoing RC [1, 4]. Clinical overstaging
occurs less often, but still in 22–27% of tumors [1, 5]. Up to
30% of patients withMIBC at TURBT have non-MIBC at RC
[5]. These discrepancies between cT-stage and pT-stage have
consequences for patient management and counseling.
Several studies have evaluated the eﬀect on progno-
sis of tumor downstaging from MIBC at TURBT to a
nonmuscle-invasive stage at RC. However, these studies
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report conflicting results: some reported perfect long-term
survival rates for patients with tumor downstaging [1, 5–
10] while another study reported no survival advantage
[11]. Furthermore, the inclusion of patients treated with
neoadjuvant systemic chemotherapy and/or radiotherapy [5,
7, 9, 11] and known lymph node metastases at RC [7, 8]
complicate the interpretation of the results in these studies.
The current study was performed in order to gain
better insight in the impact of downstaging between TURBT
and RC on cancer-specific and recurrence-free survival in
patients with initial MIBC.
2. Materials and Methods
A population-based series of 1,409 patients withMIBC, diag-
nosed between January 1, 1989 and December 31, 2005, was
identified through the population-based cancer registry in
the region of the Comprehensive Cancer Centre East in the
Netherlands. This cancer centre covers a catchment area of
1.3 million inhabitants and registers all new patients diag-
nosed with cancer. Bladder cancer is diagnosed and treated
in seven centers in this area: one university clinic (Radboud
University Nijmegen Medical Centre) and six community
hospitals: Canisius Wilhelmina Hospital in Nijmegen, Rijn-
state Hospital in Arnhem, Hospital St. Jansdal in Harderwijk,
Slingeland Hospital in Doetinchem, Hospital Gelderse Vallei
in Ede, and Maas hospital in Boxmeer. After institutional
review board approval was obtained, detailed clinical and
pathological data of these 1,409 patients were collected
retrospectively by reviewing hospital charts between October
2007 and September 2008. Data were collected by use of
standardized case record forms.
For the current study, we included all patients who
underwent RC (N = 643). To determine the percentage of
tumor downstaging, patients who received neoadjuvant ther-
apy (N = 111) and patients with unknown pT-stage after RC
(N = 24) were excluded. 38 patients were excluded because
of incomplete data. For further analyses on the characteristics
and survival of patients, those with nonurothelial cell tumors
(N = 80) and patients with known metastasis (N+/M+
disease) at time of diagnosis (N = 15) were also excluded.
Consequently, 375 patients were available for all analyses.
Maximal cT-stage was determined by pathology exam-
ination of the TURBT specimen and imaging (IVU, chest
radiography, CT, MRI, and/or bone scans). Pathologic stag-
ing was determined by examination of the RC specimen and,
when available, lymph nodes derived from the lymph node
dissection.
All specimens were examined by staﬀ pathologists with
expertise in genitourinary pathology in four pathology lab-
oratories. The 5th edition (1997) of the International Union
Against Cancer (IUCC) [12], TNM staging system was used
to classify the cT- and pT stage of all patients. For patients
who underwent surgery before 1997, when the 4th edition
(1987) was used, we recoded their pathologic stage into the
5th edition.
Disease outcomes were defined as bladder cancer-specific
survival and recurrence-free survival (RFS). Because the
cause of death is not available in the cancer registry, the hos-
pital charts and the Municipality Population Registry, blad-
der cancer-specific survival could not be calculated. Instead,
relative survival (RS) was calculated as a good approximation
of cancer specific survival [13]. In these analyses the crude
survival is adjusted for expected mortality according to
annual life tables of the general population according to age,
gender, and calendar period distribution. RFS was calculated
as the time from RC to the date of the first documented
clinical recurrence. If patients had not experienced recurrent
disease, they were censored at the date of last followup or
time of death. Because we could not retrieve accurate data
regarding the RFS for 2 patients, RFS was based on 373
patients.
RS was modeled using a multivariable generalized linear
model with an assumed Poisson distribution for the observed
number of deaths. RFS was calculated using the Kaplan
Meier method. Diﬀerences in survival rates were assessed for
statistical significance using the log-rank test.
All analyses of RFS were performed using SPSS version
16.0, Inc, Chicago, Il, USA. The RS was determined using
SAS version 9.1 (Cary, NC).
3. Results
In total, 643 patients with MIBC received RC. After exclusion
of the neoadjuvant treated patients, and the patients with
incomplete data, 470 patients remained. In 22.8% (N = 107)
of these patients the tumor showed downstaging to a non-
muscle invasive stage. As described before, for subsequent
analyses patients with non-UC andmetastasized disease were
also excluded.
3.1. Clinical and Pathological Characteristics of the Total Study
Population. The study population consisted of 375 patients.
Baseline characteristics are presented in Table 1. Median age
of the total study population was 68.3 years. The male:female
ratio was 3.3 : 1. For 344 patients, the maximal cT-stage was
based on TURBT. 31 patients had a higher cT-stage based on
imaging techniques.
Pathological evaluation of the cystectomy specimen
showed muscle-invasion in 276 (73.6%) patients while 99
(26.4%) patients were downstaged to a nonmuscle invasive
stage (i.e., pT0, pTis, or pT1). The presence of hydronephro-
sis was the only precystectomy variable that showed signif-
icant diﬀerence between both groups. In the downstaged
group 12.1% of patients had hydronephrosis compared to
28.3% in the group of patients without tumor downstaging
(P = .032).
In the group of patients with tumor downstaging, 62
(16.5%) patients had no tumor left in their RC specimen
(pT0), 20 (5.3%) had pT1, and 17 (4.5%) had pTis. 4 (4.0%)
patients (2 pTis and 2 pT1) had positive lymph nodes (pN+)
at RC, 60 (60.6%) had negative lymph nodes (pN0) and
for 35 (35.4%) patients, the N-status was unknown. Among
cases without tumor downstaging these numbers were 46
(16.7%), 155 (56.2%), and 75 (27.1%) patients, respectively.
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Table 1: Baseline characteristics of the total study population.
Variable
Total (N = 375) Downstaged
(N = 99)
Not downstaged
(N = 276)
Precystectom N N N
Population sex (%)
Total 375 99 276
Male 287 (76.5) 77 (78.8) 210 (76.1)
Female 88 (23.5) 22 (22.2) 66 (23.9)
History of other malignancy (%) 63 (16.8) 21 (21.2) 42 (16.3)
Comorbidity (%) 235 (62.3) 58 (58.6) 177 (64.1)
Hydronephrosis (%) 90 (24.0) 12 (12.1)∗ 78 (28.3)∗
Tumor grade TURBT specimen (%)
I 0 (0.3) 0 (0.0) 1 (0.4)
II 41 (10.9) 15 (15.2) 26 (9.4)
III 304 (81.1) 74 (74.7) 230 (83.3)
Unknown 29 (7.7) 10 (10.1) 19 (6.9)
Concomitant CIS in TURBT specimen (%) 74 (19.7) 25 (25.2) 49 (17.8)
Median age at cystectomy in years (range) 68.3 (33.6–94.6) 66.4 (36.0–84.2) 68.6 (33.6–94.6)
Median time between TURBT and RC in days
(range)
43.8 (3.7–412.5) 47.5 (3.7–127.8) 43.8 (3.7–412.5)
T-stage RC specimen
T0 62 (16.5)
T1 20 (5.3)
Tis 17 (4.5)
≥T2 276 (73.6)
Grade (%)
I 1 (0.3) 0 (0.0) 1 (0.4)
II 24 (6.4) 2 (2.0) 22 (8.0)
III 234 (62.4) 19 (19.2) 215 (77.9)
None 62 (16.5) 62 (62.6) 0 (0)
Unknown 54 (14.4) 16 (16.2) 38 (13.7)
N-stage PLND specimen (%)
N0 215 (57.3) 60 (60.6) 155 (56.2)
N+ 50 (13.3) 4 (4.0)∗ 46 (16.7)∗
Nx 110 (29.4) 35 (35.4) 75 (27.1)
Concomitant CIS in RC specimen (%) 106 (28.3) 26 (26.3) 80 (29.0)
∗
Chi-square test: P < .05.
3.2. Survival Analysis. Median followup time for all patients
was 7.7 years (range 0.9–19.0). Table 2 and Figure 1 show
the 1-, 3-, and 5-year RS rates for all studied patients.
The 5-year RS for patients with a downstaged tumor was
84.9% compared to 53.4% for patients who appeared to have
muscle-invasion in the RC specimen (P < .001). Among the
patients with tumor downstaging, those who had no tumor
left showed the best RS at 5 years after surgery: 93.9%
compared to 64.7% and 80.7% for patients with a pT1 stage
(P = .042) and pTis stage (P = .25), respectively.
Disease recurrence occurred in 137 (36.5%) of 375 pa-
tients. Of these patients 12 had a downstaged tumor and 125
had a muscle-invasive tumor at RC. As depicted in Table 2,
patients in whom disease was downstaged from ≥cT2 to a
nonmuscle-invasive tumor stage at RC demonstrated a RFS
of 85.2% compared to 49.9% for patients who had a muscle-
invasive tumor at RC (P < .001). The 12 patients who
suﬀered from recurrences were equally distributed over the
diﬀerent stages (pT0, pT1, pTis). The 5-year RFS of the
total population with downstaged tumors (N = 99) was
85.2%. After 5 years of followup 91.9%, 78.6%, and 69.6%
of these patients with a pT0, pT1, and pTis stage were free
of recurrence. Although the best RFS was demonstrated by
patients with a pT0 tumor stage, the diﬀerences among
downstaged patients did not reach statistical significance.
4. Discussion
The current study provides insight in the survival of patients
with MIBC downstaged to a nonmuscle-invasive tumor stage
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Table 2: Relative survival (RS) and recurrence free survival (RFS) after 1, 3, and 5 years of followup.
Survival Group N 1 year (±SE) 3 years (±SE) 5 years (±SE)
RS All 375 88.4 (1.9) 65.8 (2.8) 61.7 (3.1)
Downstaged 99 100.7 (1.5) 91.3 (4.2) 84.9 (5.6)
T0 62 99.0 (2.3) 98.3 (3.9) 93.9 (6.2)
T1 20 103.8 84.1 (10.9) 64.7 (13.5)
Tis 17 103.1 75.0 (13.1) 80.7 (14.1)
Not Downstaged 276 84.0 (2.4) 56.7 (3.3) 53.4 (3.6)
T2 84 93.0 (3.3) 79.3 (5.3) 76.0 (6.1)
T3 160 83.0 (3.2) 50.4 (4.4) 46.6 (4.7)
T4 32 65.3 (8.9) 28.2 (8.8) 27.5 (9.6)
RFS All 375 77.2 (2.2) 61.3 (2.7) 59.6 (2.7)
Downstaged 99 97.9 (1.5) 88.7 (3.4) 85.2 (4.0)
T0 62 100 94.3 (3.2) 91.9 (3.9)
T1 20 89.5 (7.0) 78.6 (9.5) 78.6 (9.5)
Tis 17 100 81.2 (9.8) 69.6 (13.6)
Not Downstaged 276 69.4 (2.9) 51.0 (3.2) 49.0 (3.2)
T2 84 84.8 (4.0) 72.7 (5.1) 70.7 (5.3)
T3 160 64.0 (3.9) 42.3 (4.2) 42.3 (4.2)
T4 32 51.2 (10.0) 26.5 (9.7) 26.1 (9.7)
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Figure 1: Kaplan-Meier curves of the relative survival (RS) for: (a) all patients, downstaged and not downstaged patients, (b) Not downstaged
patients and patients with a pT2, pT3, and pT4 stage, and (c) Downstaged patients and patients with a pT0, pTis, and pT1 stage.
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or pT0 after TURBT. All patients were treated by RC and
were unexposed to any kind of (neo)adjuvant therapy. In
26.4% of these patients the tumor was downstaged. Not
surprisingly, patients who experienced tumor downstaging
showed a significantly better survival compared to patients
with residual muscle-invasive tumor stages at RC. Patients
who did not demonstrate downstaging were at highest risk
of recurrence and mortality. They showed a RFS of 49.9%
and a RS of 53.4% at 5 years. Among patients with tumor
downstaging those who had no tumor left showed the best
RS and RFS of 93.9% and 91.9%, respectively, at 5 years after
surgery. For patients with tumor downstaging to pT1, and
pTis, the RS at 5 years was 64.7% and 80.7%, respectively
and the RFS at the same time point was 78.6% and 69.6%,
respectively.
A discrepancy between clinical and pathologic staging
is a common finding in clinical practice with prognostic
consequences that have been described in previous reports.
Nielsen et al. [7] assessed RFS among patients noted to
have MIBC on TURBT but were subsequently found to
have NMIBC at RC. Of the 112 patients, 25 (22.3%) were
downstaged to non-MIBC at RC. They demonstrated a
significantly better RFS for downstaged patients (84.0%)
compared to those who were not downstaged (66.7%). Even
after adjusting for lymph node status or chemotherapy in
a multivariable model, a threefold reduction in recurrence
risk with downstaging was seen. Shariat et al. [5] studied a
group of 490 patients who had a muscle-invasive cT-stage
and were treated with or without (neo)adjuvant therapy
and RC. They found that patients who had nonmuscle
invasive pathological stage showed a lower probability of
bladder cancer recurrence and disease-specific mortality
than patients who remained muscle-invasive [5]. Recently,
Isbarn et al. [6] described that in 208 patients with cT2N0
stage bladder cancer a lower T-stage at RC correlated with
improved outcomes relative to those with pT2N0 disease.
Patients who received peri-operative chemotherapy were
excluded from their analysis. When all downstaged cases
were grouped (pT0, pTa, and pT1) a significantly better
recurrence-free and bladder cancer specific survival was
found for these patients compared to pT2 cases. In addition,
they proposed a trend eﬀect on survival according to the
extent of TURBT downstaging. Except for a better RS for
patients with a pT0 stage after RC compared to a pT1 stage
there were no significant diﬀerences in survival among the
downstaged patients in our study. Probably these groups of
patients were too small (N = 62, N = 20, and N = 17 for
pT0, pT1, and pTis, resp.) to detect a significant intragroup
diﬀerence. However, both the RS and the RFS among patients
with tumor downstaging showed a trend towards a better
survival according to the extent of the invasiveness and
volume of the tumor. Data from Herr [14] also suggest that
downstaging by TURBT can oﬀer a survival benefit. They
presented the outcomes of patients with MIBC treated by
TURBT only. The disease specific survival rate in their series
for patients with stage cT0 on restaging TURBT was 82%
compared to 57% for patients with cT1 disease on restaging
TURBT (P = .003). In opposition, in a more historical series,
Thrasher et al. found no improved outcome after tumor
downstaging. They examined the survival advantage of a
stage pT0 in 66 of 433 patients (213 had clinical MIBC) who
underwent RC for bladder cancer. They found that patients
with a pT0 cystectomy specimen did not have a survival
advantage over those who had similar cT- and pT-stage
[11].
Although patients with tumor downstaging to a pT0
stage had the best RS and RFS there was still disease
attributable mortality in this group of patients. Apart from
the possibility that the pathologic pT0 stage was inaccurate
or the recurrences were of other origin than the bladder,
the most logical explanation for this observation is the
occurrence of undetected metastases [10]. In the population
evaluated by Isbarn et al. there were no recurrences or
bladder cancer specific deaths after 5 years of followup
among the patients downstaged to pT0 stage, which is in
conflict with the RS and RFS of pT0N0 patients found
in our study (93.9% and 91.9%, resp.). Taken together,
these findings suggest that, although patients with a pT0
tumor constitutes a subgroup with the best survival among
patients with tumor downstaging, having no tumor left in
the cystectomy specimen may still come along with a small
excess of bladder cancer deaths.
The use of neoadjuvant chemotherapy for cT2 disease is
still under debate. In its most recent guideline the European
Association of Urology indicates that neoadjuvant cisplatin-
based combination chemotherapy should be considered in
MIBC [15]. As mentioned before, Isbarn et al. found a 5-year
RFS and cancer specific mortality of both 100% for patients
downstaged to pT0, pTa and pTis. The authors concluded
that neoadjuvant chemotherapy may not be necessary nor
beneficial in cT2 patients downstaged to pT0, pTa or pTis by
TURBT. However, the RS and RFS for pT0 and pTis after 5
years of followup (93.9% and 91.9% for pT0, 80.7 and 69.6%
for pTis) in our study does not underline this statement.
Apart from the fact that it is not possible to predict the degree
of tumor downstaging after TURBT, the recommendation
to withhold neoadjuvant chemotherapy for all cT2 patients
after a complete TURBT cannot be taken based on the
completeness of a TURBT alone.
Our finding that radical resection of MIBC at TURBT
resulting in a nonmuscle invasive tumor stage or pT0 at
RC is associated with improved survival may have several
explanations. Complete resection at TURBT may indepen-
dently provide a protective eﬀect on outcome. On the other
hand it is possible that initially less deeply invasive or smaller
tumors before TURBT and, thus, lower residual tumor
volume after TURBT can confound the benefit of TURBT
related downstaging [6]. We found that patients with tumor
downstaging showed less often hydronephrosis. This may
suggest that patients with tumor downstaging had less often
deeply invasive tumors and/or a lower tumor volume at time
of diagnosis.
Our findings suggest that a thorough and complete
TURBT may be warranted in most patients who are candi-
dates for RC and have MIBC at TURBT. However, such rec-
ommendations may not apply to patients with tumors >T2
tumors in whom complete TURBT may lead to perforation
and its consequences.
6 ISRN Urology
This study has some limitations. First, cause of death was
not available. Therefore, RS analyses were used to approx-
imate the cancer-specific survival. Because relative survival
analysis does not adjust for smoking habits, the use of RS
may have slightly overestimated bladder cancer mortality.
Furthermore, our study has limitations inherent to retro-
spective analysis: the TURBT and cystectomy procedures
were performed by diﬀerent surgeons, the specimens were
evaluated by multiple pathologists overtime, and central
review of pathology was not possible. This might have caused
some misclassification of staging and additional variability
in prognosis after cystectomy. On the other hand, it reflects
real-life urologic practice.
5. Conclusions
Tumor downstaging is a common finding; 26.4% of patients
with a clinical muscle-invasive tumor were downstaged to a
nonmuscle-invasive stage. Patients with tumor downstaging
have a ∼30% better recurrence-free survival and relative
survival compared to those without. Consequently tumor
downstaging is probably the most favorable marker for
prognosis after RC.
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